A renowned leader in neuroscience research, Dr. Robin Carhart-Harris heads the Centre for Psychedelic Research at Imperial College London. He has designed a number of functional brain imaging studies with psilocybin, LSD, MDMA, and DMT and completed multiple clinical trials of psilocybin for depression. Dr. Carhart-Harris has published over 100 papers in peer-reviewed scientific journals. His research has, among many other findings, shown that 67% of patients who underwent psilocybin treatment experienced remission of their treatment-resistant depression at 1 week post-treatment. He has helped elucidate the neural and biochemical underpinnings of psychedelic molecules and their therapeutic effects. He holds a PhD in Psychopharmacology from the University of Bristol, where he studied with his close collaborator and world-famous neuropsychopharmacologist Dr. David Nutt.
Omar I. Abdel-Wahab
Scientific Advisor at Envisagenics
Scientific Advisor at Refuge Biotech
Scientific Advisor at Next Biosciences
Scientific Advisor at Biophytis
Scientific Advisor at NovAccess Global
Scientific Advisor at Curtana Pharmaceuticals